A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India

BACKGROUND: This phase 2/3 immunobridging study evaluated the safety and immunogenicity of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (SII-ChAdOx1 nCoV-19), manufactured in India at the Serum Institute of India Pvt Ltd (SIIPL), following technology transfer from the AstraZeneca. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Prasad S, Padmapriyadarsini, Chandrasekaran, Vekemans, Johan, Bavdekar, Ashish, Gupta, Madhu, Kulkarni, Praveen, Garg, B S, Gogtay, Nithya J, Tambe, Muralidhar, Lalwani, Sanjay, Singh, Kiranjit, Munshi, Renuka, Meshram, Sushant, Selvavinayagam, T S, Pandey, Krishna, Bhimarasetty, Devi Madhavi, Ramakrishnan, S R, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Vadakkedath, Rajeev, Bonhomme, Cyrille J, Thakar, Madhuri, Kurle, Swarali N, Kelly, Elizabeth J, Gautam, Manish, Gupta, Nivedita, Panda, Samiran, Bhargava, Balram, Shaligram, Umesh, Kapse, Dhananjay, Gunale, Bhagwat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629682/
https://www.ncbi.nlm.nih.gov/pubmed/34870133
http://dx.doi.org/10.1016/j.eclinm.2021.101218

Ejemplares similares

Ejemplares similares